|
Variable
| |
Total population
| | |
Females
| | |
Males
| |
|---|
|
HR
|
95%CI
|
p-value
|
HR
|
95%CI
|
p-value
|
HR
|
95%CI
|
p-value
|
|---|
|
Age
|
1.17
|
1.10–1.25
|
< 0.0001
|
1.20
|
1.07–1.34
|
0.002
|
1.20
|
1.10–1.30
|
< 0.0001
|
|
IHD
|
1.23
|
0.74–2.03
|
0.42
|
1.13
|
0.44–2.89
|
0.80
|
1.05
|
0.55–2.01
|
0.88
|
|
Hypertension
|
1.17
|
0.71–1.93
|
0.53
|
1.85
|
0.72–4.71
|
0.20
|
1.04
|
0.58–1.89
|
0.89
|
|
Diabetes
|
1.25
|
0.82–1.93
|
0.30
|
1.90
|
0.86–4.18
|
0.11
|
0.87
|
0.50–1.50
|
0.61
|
|
AECI/ARB
|
1.00
|
0.62–1.61
|
0.99
|
0.73
|
0.32–1.66
|
0.45
|
1.30
|
0.72–2.36
|
0.39
|
|
Beta blockers
|
0.77
|
0.48–1.24
|
0.28
|
0.76
|
0.35–1.65
|
0.48
|
0.78
|
0.42–1.46
|
0.43
|
|
Atrial fibr.
|
2.23
|
1.30–3.86
|
0.004
|
4.66
|
1.69–12.83
|
0.003
|
1.71
|
0.85–3.45
|
0.13
|
|
Hb < 120 g/L
|
1.42
|
0.82–2.49
|
0.21
|
2.52
|
1.07–5.94
|
0.04
|
1.03
|
0.44–2.40
|
0.94
|
|
EF < 40%
|
1.79
|
0.96–3.33
|
0.07
|
3.57
|
1.14–11.20
|
0.03
|
1.41
|
0.63–3.16
|
0.40
|
|
TSP-1 rs1478604, T/T
|
1.62
|
1.03–2.53
|
0.04
|
3.18
|
1.35–7.50
|
0.008
|
1.18
|
0.68–2.05
|
0.56
|
- ACEI angiotensin convering enzyme inhibitors, ARB angiotensin receptor inhibitors, EF ejection fraction, HR hazard ratio
